PACMEL: A phase 1 dose escalation trial of trametinib (GSK1120212) in combination with paclitaxel

European Journal of Cancer

Volumn 51, Issue 3, 2015, Pages 359-366

  Coupe, Nicholas ^a   Corrie, Pippa ^b   Hategan, Mirela ^b   Larkin, James ^c   Gore, Martin ^c   Gupta, Avinash ^a   Wise, Adelyn ^d   Suter, Sam ^a   Ciria, Cristian ^e   Love, Sharon ^e   Collins, Linda ^d   Middleton, Mark R ^a,f  

^a OXFORD UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^b CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^c INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e UNIVERSITY OF OXFORD   (United Kingdom)

^f NIHR OXFORD BIOMEDICAL RESEARCH CENTRE   (United Kingdom)

Author keywords

BRAF; MEK; Melanoma; Phase 1; Trametinib; Trial

Indexed keywords

B RAF KINASE; PACLITAXEL; TRAMETINIB; ANTINEOPLASTIC AGENT; PYRIDONE DERIVATIVE; PYRIMIDINONE DERIVATIVE;

ACUTE KIDNEY TUBULE NECROSIS; ADULT; ADVANCED CANCER; AGED; ALOPECIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CENTRAL SEROUS RETINOPATHY; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CLINICAL ARTICLE; CUTANEOUS MELANOMA; DIARRHEA; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GENE MUTATION; HUMAN; HYPERTENSION; INFECTION; INTRAOCULAR HYPERTENSION; KIDNEY FAILURE; LIVER FUNCTION TEST; LIVER TOXICITY; MALE; MAXIMUM TOLERATED DOSE; MELANOMA; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PERIPHERAL EDEMA; PHASE 1 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SIDE EFFECT; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG ADMINISTRATION; MIDDLE AGED; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; SKIN NEOPLASMS;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MELANOMA; MIDDLE AGED; PACLITAXEL; PYRIDONES; PYRIMIDINONES; SKIN NEOPLASMS;

EID: 84922640349     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2014.11.018     Document Type: Article

References (31)

1. R. Siegel, D. Naishadham, and A. Jemal Cancer statistics CA Cancer J Clin 63 1 2013 11 30
2. J.M. Kyriakis, H. App, X.F. Zhang, P. Banerjee, D.L. Brautigan, and U.R. Rapp Raf-1 activates MAP kinase-kinase Nature 358 6385 1992 417 [Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.]
3. M. Roring, and T. Brummer Aberrant B-Raf signaling in human cancer - 10 years from bench to bedside Crit Rev Oncog 17 1 2012 97 121 [Research Support, Non-U.S. Gov't Review]
4. P.B. Chapman, A. Hauschild, C. Robert, J.B. Haanen, P. Ascierto, and J. Larkin Improved survival with vemurafenib in melanoma with BRAF V600E mutation N Engl J Med 364 26 2011 2507 2516 [Clinical Trial, Phase III Comparative Study Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't]
5. K.T. Flaherty, I. Puzanov, K.B. Kim, A. Ribas, G.A. McArthur, and J.A. Sosman Inhibition of mutated, activated BRAF in metastatic melanoma N Engl J Med 363 9 2010 809 819 [Clinical Trial, Phase I Multicenter Study Research Support, Non-U.S. Gov't]
6. A. Hauschild, J.J. Grob, L.V. Demidov, T. Jouary, R. Gutzmer, and M. Millward Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial Lancet 380 9839 2012 358 365 [Clinical Trial, Phase III Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't]
7. K.T. Flaherty, J.R. Infante, A. Daud, R. Gonzalez, R.F. Kefford, and J. Sosman Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations N Engl J Med 367 18 2012 1694 1703 [Clinical Trial, Phase I Clinical Trial, Phase II Randomized Controlled Trial Research Support, Non-U.S. Gov't]
8. G.S.D. Long, H. Gogas, E. Levchenko, F. de Braud, and J.M.G. Larkin COMBI-d: a randomized, double-blinded, Phase III study comparing the combination of dabrafenib and trametinib to dabrafenib and trametinib placebo as first-line therapy in patients (pts) with unresectable or metastatic BRAFV600E/K mutation-positive cutaneous melanoma J Clin Oncol 32 2014 5s [suppl.; abstr. 9011]
9. A.S. Yang, and P.B. Chapman The history and future of chemotherapy for melanoma [Review] Hematol Oncol Clin North Am 23 3 2009 583 597 x
10. F.S. Hodi, S.J. O'Day, D.F. McDermott, R.W. Weber, J.A. Sosman, and J.B. Haanen Improved survival with ipilimumab in patients with metastatic melanoma N Engl J Med 363 8 2010 711 723 [Clinical Trial, Phase III Comparative Study Multicenter Study Randomized Controlled Trial]
11. S.L. Topalian, M. Sznol, D.F. McDermott, H.M. Kluger, R.D. Carvajal, and W.H. Sharfman Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab J Clin Oncol 32 10 2014 1020 1030 [Clinical Trial Research Support, Non-U.S. Gov't]
12. A.H.F. Ribas, R. Kefford, O. Hamid, A. Daud, and J.D. Wolchok Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (pts) with melanoma (MEL) J Clin Oncol 32 2014 5s [suppl; abstr LBA9000]
13. F.S. Hodi, M. Sznol, H.M. Kluger, D.F. McDermott, R.D. Carvajal, and D.P. Lawrence Long-term survival of ipilimumab-naive patients (pts) with advanced melanoma (MEL) treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) in a phase I trial J Clin Oncol 32 2014 5s [suppl; abstr 9002]
14. M. Kortylewski, P.C. Heinrich, M.E. Kauffmann, M. Bohm, A. MacKiewicz, and I. Behrmann Mitogen-activated protein kinases control p27/Kip1 expression and growth of human melanoma cells Biochem J 357 Pt 1 2001 297 303 [Research Support, Non-U.S. Gov't]
15. K. Satyamoorthy, G. Li, M.R. Gerrero, M.S. Brose, P. Volpe, and B.L. Weber Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation Cancer Res 63 4 2003 756 759 [Research Support, U.S. Gov't, P.H.S.]
16. T.T. Tan, K. Degenhardt, D.A. Nelson, B. Beaudoin, W. Nieves-Neira, and P. Bouillet Key roles of BIM-driven apoptosis in epithelial tumors and rational chemotherapy Cancer Cell 7 3 2005 227 238 [Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.]
17. J.P. MacKeigan, T.S. Collins, and J.P. Ting MEK inhibition enhances paclitaxel-induced tumor apoptosis J Biol Chem 275 50 2000 38953 38956 [Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.]
18. H.M. McDaid, and S.B. Horwitz Selective potentiation of paclitaxel (taxol)-induced cell death by mitogen-activated protein kinase kinase inhibition in human cancer cell lines Mol Pharmacol 60 2 2001 290 301 [Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.]
19. R. Xu, N. Sato, K. Yanai, T. Akiyoshi, S. Nagai, and J. Wada Enhancement of paclitaxel-induced apoptosis by inhibition of mitogen-activated protein kinase pathway in colon cancer cells Anticancer Res 29 1 2009 261 270
20. P.A. Janne, A.T. Shaw, J.R. Pereira, G. Jeannin, J. Vansteenkiste, and C. Barrios Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study Lancet Oncol 14 1 2013 38 47 [Clinical Trial, Phase II Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't]
21. A. Gupta, S. Love, A. Schuh, M. Shanyinde, J.M. Larkin, and R. Plummer DOC-MEK: a double-blind randomized phase II trial of docetaxel with or without selumetinib in wild-type BRAF advanced melanoma Ann Oncol 25 5 2014 968 974 [Research Support, Non-U.S. Gov't]
22. T. Yamaguchi, T. Yoshida, R. Kurachi, J. Kakegawa, Y. Hori, and T. Nanayama Identification of JTP-70902, a p15(INK4b)-inductive compound, as a novel MEK1/2 inhibitor Cancer Sci 98 11 2007 Nov 1809 1816
23. K.T. Flaherty, C. Robert, P. Hersey, P. Nathan, C. Garbe, and M. Milhem Improved survival with MEK inhibition in BRAF-mutated melanoma N Engl J Med 367 2 2012 107 114 [Clinical Trial, Phase III Comparative Study Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't]
24. J.M. Kirkwood, L. Bastholt, C. Robert, J. Sosman, J. Larkin, and P. Hersey Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma Clin Cancer Res 18 2 2012 555 567 [Clinical Trial, Phase II Comparative Study Multicenter Study Randomized Controlled Trial Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't]
25. K.B. Kim, R. Kefford, A.C. Pavlick, J.R. Infante, A. Ribas, and J.A. Sosman Phase II study of the MEK1/MEK2 inhibitor trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor J Clin Oncol 31 4 2013 482 489 [Clinical Trial, Phase II Multicenter Study Research Support, Non-U.S. Gov't]
26. A.G. Gilmartin, M.R. Bleam, A. Groy, K.G. Moss, E.A. Minthorn, and S.G. Kulkarni GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition Clin Cancer Res 17 5 2011 989 1000
27. J.R. Brahmer, S.S. Tykodi, L.Q. Chow, W.J. Hwu, S.L. Topalian, and P. Hwu Safety and activity of anti-PD-L1 antibody in patients with advanced cancer N Eng J Med 366 26 2012 2455 2465
28. G.S. Falchook, K.D. Lewis, J.R. Infante, M.S. Gordon, N.J. Vogelzang, and D.J. DeMarini Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial Lancet Oncol 13 8 2012 782 789 [Clinical Trial, Phase I Multicenter Study Research Support, Non-U.S. Gov't Webcasts]
29. P.B. Chapman, A. Hauschild, C. Robert, J.B. Haanen, P. Ascierto, and J. Larkin Improved survival with vemurafenib in melanoma with BRAF V600E mutation N Eng J Med 364 26 2011 2507 2516
30. P.A. Ascierto, D. Schadendorf, C. Berking, S.S. Agarwala, C.M. van Herpen, and P. Queirolo MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study Lancet Oncol 14 3 2013 249 256 [Clinical Trial, Phase II Multicenter Study Research Support, Non-U.S. Gov't]
31. J.R. Infante, K.P. Papadopoulos, J.C. Bendell, A. Patnaik, H.A. Burris III, and D. Rasco A phase 1b study of trametinib, an oral Mitogen-activated protein kinase kinase (MEK) inhibitor, in combination with gemcitabine in advanced solid tumours Eur J Cancer 49 9 2013 2077 2085